Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.

Lambertini M, Bruzzi P, Poggio F, Pastorino S, Gardin G, Clavarezza M, Bighin C, Pronzato P, Del Mastro L.

Support Care Cancer. 2015 Aug 27. [Epub ahead of print]

PMID:
26306520
2.

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.

Del Mastro L, Cazzaniga M, Solidoro P, Generali D, Bianchi G, Testore F, De Placido S.

Future Oncol. 2015 Aug;11(16):2251-4. doi: 10.2217/fon.15.134. No abstract available.

PMID:
26260802
3.

Exploring the safety of chemotherapy for treating breast cancer during pregnancy.

Lambertini M, Kamal NS, Peccatori FA, Del Mastro L, Azim HA Jr.

Expert Opin Drug Saf. 2015 Sep;14(9):1395-408. doi: 10.1517/14740338.2015.1061500. Epub 2015 Jul 3.

PMID:
26118333
4.

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L.

Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22.

PMID:
26099741
5.

Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.

Bogina G, Lunardi G, Coati F, Zamboni G, Gori S, Bortesi L, Marconi M, Cassandrini PA, Turazza M, Cortesi L, DeMatteis E, Ficarra G, Ibrahim T, Serra P, Medri L, Giraudi S, Lambertini M, Carli F, Foglietta J, Sidoni A, Nunzi M, Ficorella C, Diadema MR, Del Mastro L.

Tumori. 2015 Jul 24;101(4):398-403. doi: 10.5301/tj.5000323. Epub 2015 May 22.

PMID:
26045108
6.

Pharmacokinetics of trastuzumab in haemodialysis.

Gori S, Foglietta J, Lunardi G, Inno A, Cardinali B, Millo E, Del Mastro L, Nunzi EG, Crinò L.

Breast J. 2015 May-Jun;21(3):329-31. doi: 10.1111/tbj.12407. Epub 2015 Mar 19. No abstract available.

PMID:
25790224
7.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.

Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.

PMID:
25740286
8.

Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer.

Levaggi A, De Maria A, Dozin B, Iacono G, Bighin C, Giraudi S, Lambertini M, D'Alonzo A, Poggio F, Pronzato P, Del Mastro L.

Anticancer Res. 2014 Jul;34(7):3715-20.

PMID:
24982392
9.

Fertility issues in young breast cancer patients: what women want.

Lambertini M, Pinto AC, Del Mastro L.

J Thorac Dis. 2014 Jun;6(6):584-8. doi: 10.3978/j.issn.2072-1439.2014.06.12. No abstract available.

10.

Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab.

Cardinali B, Lunardi G, Millo E, Armirotti A, Damonte G, Profumo A, Gori S, Iacono G, Levaggi A, Del Mastro L.

Anal Bioanal Chem. 2014 Jul;406(18):4557-61. doi: 10.1007/s00216-014-7842-4. Epub 2014 May 15.

PMID:
24828979
11.

Follow-up of patients with early breast cancer: is it time to rewrite the story?

Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, Gori S, Del Mastro L.

Crit Rev Oncol Hematol. 2014 Aug;91(2):130-41. doi: 10.1016/j.critrevonc.2014.03.001. Epub 2014 Mar 22. Review.

12.

A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes.

Canavese G, Bruzzi P, Catturich A, Vecchio C, Tomei D, Del Mastro L, Carli F, Guenzi M, Lacopo F, Dozin B.

Eur J Surg Oncol. 2014 Jul;40(7):835-42. doi: 10.1016/j.ejso.2014.03.005. Epub 2014 Mar 16.

PMID:
24684810
13.

Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.

Gori S, Lunardi G, Inno A, Foglietta J, Cardinali B, Del Mastro L, Crinò L.

Ann Oncol. 2014 Apr;25(4):912-3. doi: 10.1093/annonc/mdu041. No abstract available.

14.

Targeting bone metastatic cancer: Role of the mTOR pathway.

Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D.

Biochim Biophys Acta. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. Epub 2014 Feb 5. Review.

PMID:
24508774
15.

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.

Sini V, Lunardi G, Cirillo M, Turazza M, Bighin C, Giraudi S, Levaggi A, Piccioli P, Bisagni G, Gnoni R, Stridi G, Porpiglia M, Picardo E, Ponzone R, Marenco D, Mansutti M, Puglisi F, Del Mastro L.

Br J Cancer. 2014 Mar 4;110(5):1133-8. doi: 10.1038/bjc.2014.2. Epub 2014 Jan 21.

16.

Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.

Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G, Pronzato P, Bruzzi P.

Cancer Treat Rev. 2014 Jun;40(5):675-83. doi: 10.1016/j.ctrv.2013.12.001. Epub 2013 Dec 8. Review.

PMID:
24360817
17.

Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.

Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L.

Endocr Relat Cancer. 2014 Jan 21;21(1):R51-65. doi: 10.1530/ERC-13-0335. Print 2014 Feb. Review.

18.

The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).

Lambertini M, Del Mastro L, Bellodi A, Pronzato P.

Crit Rev Oncol Hematol. 2014 Jan;89(1):112-28. doi: 10.1016/j.critrevonc.2013.08.006. Epub 2013 Aug 29. Review.

PMID:
24041627
19.

Anthracycline-free therapy for HER2-amplified breast cancer.

Gennari A, Del Mastro L.

Lancet Oncol. 2013 Oct;14(11):1037-8. doi: 10.1016/S1470-2045(13)70410-8. Epub 2013 Sep 3. No abstract available.

PMID:
24007747
20.

Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.

Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Gruppo Italiano Mammella.

Oncologist. 2013;18(8):924-5. doi: 10.1634/theoncologist.2013-0222. Epub 2013 Aug 12. Erratum in: Oncologist. 2013;18(10):1149.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk